On June 18, 2020 CDDF reported that provides a neutral platform to stimulate interactions between all stakeholders involved in cancer drug development (Press release, EORTC, JUN 18, 2020, View Source [SID1234561242]). The aim of the organization is to accelerate the delivery of effective oncology agents to patients by encouraging multi-stakeholder discussions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration will foster dialogue on common issues in clinical cancer research especially with other stakeholders. Both organisations intend to organise joint workshops and offer support and endorsement in each other’s events.

"Through the partnership with EORTC, one of the most important academic clinical research organizations worldwide, we believe we are offering unique value to stimulate advancement in oncology treatment and delivery" said Professor Jaap Verweij, CDDF Managing Director. "We believe collaboration is the key to improving outcomes for cancer patients and we look forward to a strong alliance with EORTC that will help identify and overcome challenges in the development and delivery of cancer drugs and deliver swift benefits to cancer patients."

"This is an important partnership for EORTC," said Dr Denis Lacombe, EORTC Director General. "CDDF has been instrumental in discussions with regulators and other stakeholders and with our combined efforts, we can bring challenging issues to the wider oncology community producing effective outcomes."